Total Payments
$218,556
2024 Payments
$38,323
Companies
20
Transactions
166
Medicare Patients
11
Medicare Billing
$1,452
Payment Breakdown by Category
Consulting$127,857 (58.5%)
Travel$73,563 (33.7%)
Research$9,080 (4.2%)
Other$6,000 (2.7%)
Food & Beverage$1,989 (0.9%)
Education$65.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $127,857 | 47 | 58.5% |
| Travel and Lodging | $73,563 | 49 | 33.7% |
| Unspecified | $9,080 | 11 | 4.2% |
| Honoraria | $6,000 | 2 | 2.7% |
| Food and Beverage | $1,989 | 37 | 0.9% |
| Education | $65.94 | 20 | 0.0% |
Payments by Type
General
$209,475
155 transactions
Research
$9,080
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $69,452 | 66 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $34,690 | 14 | $0 (2024) |
| Travere Therapeutics, Inc. | $20,023 | 24 | $0 (2024) |
| Retrophin, Inc. | $13,907 | 13 | $0 (2019) |
| Vifor (International) Ltd. | $11,990 | 4 | $0 (2018) |
| F. Hoffmann-La Roche AG | $10,882 | 10 | $0 (2022) |
| Relypsa, Inc. | $10,879 | 7 | $0 (2020) |
| Samsung Bioepis Co., Ltd. | $7,328 | 3 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $6,949 | 1 | $0 (2018) |
| Leadiant Biosciences, Inc. | $6,292 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,323 | 22 | Alexion Pharmaceuticals, Inc. ($22,612) |
| 2023 | $12,232 | 9 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($10,516) |
| 2022 | $15,723 | 9 | Travere Therapeutics, Inc. ($8,102) |
| 2021 | $16,128 | 17 | F. Hoffmann-La Roche AG ($4,542) |
| 2020 | $21,588 | 13 | Travere Therapeutics, Inc. ($6,228) |
| 2019 | $41,343 | 25 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($15,824) |
| 2018 | $39,137 | 30 | Alexion Pharmaceuticals, Inc. ($14,638) |
| 2017 | $34,081 | 41 | Alexion Pharmaceuticals, Inc. ($17,137) |
All Payment Transactions
166 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $6,120.00 | General |
| 12/26/2024 | Samsung Bioepis Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $1,138.00 | General |
| 12/26/2024 | Samsung Bioepis Co., Ltd. | — | Food and Beverage | In-kind items and services | $70.00 | General |
| 10/25/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | — | In-kind items and services | $67.93 | Research |
| Study: A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 12 WEEKS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) • Category: NEPHROLOGY | ||||||
| 05/22/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 05/22/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $0.37 | General |
| 04/21/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $39.32 | General |
| Category: Rare Disease | ||||||
| 04/20/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | In-kind items and services | $249.24 | General |
| Category: Rare Disease | ||||||
| 04/20/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $48.67 | General |
| Category: Rare Disease | ||||||
| 04/20/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Rare Disease | ||||||
| 04/19/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | In-kind items and services | $249.24 | General |
| Category: Rare Disease | ||||||
| 04/19/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Rare Disease | ||||||
| 04/19/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $49.03 | General |
| Category: Rare Disease | ||||||
| 04/19/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $44.78 | General |
| Category: Rare Disease | ||||||
| 04/18/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | In-kind items and services | $249.24 | General |
| Category: Rare Disease | ||||||
| 04/18/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $32.84 | General |
| Category: Rare Disease | ||||||
| 04/17/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Travel and Lodging | In-kind items and services | $8,523.70 | General |
| Category: Rare Disease | ||||||
| 03/20/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $4,842.50 | General |
| Category: NEPHROLOGY | ||||||
| 02/23/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 02/02/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,866.00 | General |
| 01/29/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $13,050.00 | General |
| Category: Rare Disease | ||||||
| 01/09/2024 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 12/13/2023 | Genentech, Inc. | Gazyva (Biological) | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| Category: BioOncology | ||||||
| 11/04/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $28.51 | General |
| 09/12/2023 | Travere Therapeutics, Inc. | Thiola (Drug) | Education | In-kind items and services | $3.82 | General |
| Category: Kidney Stones | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB IN ADOLESCENT AND PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME AHUS | F. Hoffmann-La Roche AG | $3,070 | 4 |
| DUET RET-D-001 | Retrophin, Inc. | $2,400 | 1 |
| A PHASE III, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME AHUS , A PHASE III, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB IN ADOLESCENT AND PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME AHUS | F. Hoffmann-La Roche AG | $1,708 | 3 |
| A PHASE III, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME AHUS | F. Hoffmann-La Roche AG | $784.55 | 1 |
| A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 12 WEEKS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $67.93 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 24 | $7,949 | $1,452 |
Total Patients
11
Total Services
24
Medicare Billing
$1,452
Procedure Codes
1
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 24 | $7,949 | $1,452 | 18.3% |
About Laurence Greenbaum, MD, PHD
Laurence Greenbaum, MD, PHD is a Pediatric Nephrology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447278742.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Laurence Greenbaum, MD, PHD has received a total of $218,556 in payments from pharmaceutical and medical device companies, with $38,323 received in 2024. These payments were reported across 166 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($127,857).
As a Medicare-enrolled provider, Greenbaum has provided services to 11 Medicare beneficiaries, totaling 24 services with total Medicare billing of $1,452. Data is available for 1 year (2023–2023), covering 1 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Nephrology
- Location Atlanta, GA
- Active Since 07/17/2006
- Last Updated 06/06/2022
- Taxonomy Code 2080P0210X
- Entity Type Individual
- NPI Number 1447278742
Products in Payments
- SOLIRIS (Drug) $46,268
- TOLVAPTAN (Drug) $25,818
- SOLIRIS (Biological) $22,612
- Veltassa (Drug) $10,879
- Not Product Related (Medical Supply) $6,949
- Non-Covered Product (Drug) $6,928
- Cystaran (Drug) $6,292
- SAMSCA (Drug) $5,432
- OXLUMO (Drug) $4,800
- AURYXIA (Drug) $4,500
- JYNARQUE (Drug) $3,440
- GAZYVA (Biological) $3,220
- Injectafer (Drug) $2,300
- Gazyva (Biological) $1,680
- Ultomiris (Drug) $500.00
- PROCYSBI (Drug) $68.90
- Thiola (Drug) $22.48
- (815) Thiola (Drug) $14.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Nephrology Doctors in Atlanta
Rouba Garro, Md, MD
Pediatric Nephrology — Payments: $6,908
Pediatric Nephrology $6,908
Pamela Winterberg, Md, MD
Pediatric Nephrology — Payments: $74.34
Pediatric Nephrology $74.34
Jacob Humphrey, Md, MD
Pediatric Nephrology — Payments: $19.50
Pediatric Nephrology $19.50
Stephanie Jernigan, Md, MD
Pediatric Nephrology — Payments: $6.44
Pediatric Nephrology $6.44
Barry Warshaw, Md, MD
Pediatric Nephrology — Payments: $3.82
Pediatric Nephrology $3.82
Chia-Shi Wang, Md, MD
Pediatric Nephrology — Payments: $3.82
Pediatric Nephrology $3.82